NHS England and NICE have approved the use of Tirzepatide (Mounjaro®) in primary care, effective from 23rd June 2025. Commonly referred to as ‘the weight loss drug’, this medication will be available under very strict criteria during the first two years of rollout, to ensure its safe introduction into the NHS.
At this stage, eligibility is limited to patients with a BMI of 40 or higher and at least four of the following pre-diagnosed conditions:
- Hypertension
- Dyslipidaemia
- Obstructive Sleep Apnoea
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Type 2 Diabetes Mellitus
If you believe you meet this criteria, please contact us. Otherwise, we kindly ask that you do not enquire about this medication at this time.
Thank you for your understanding.